ArticleBiochemistry and biophysics reports2026
SERPINA3 facilitates malignant progression and remodels tumor immune microenvironment in glioma.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SERPINA3 as a Secreted-Protein Biomarker Associated with Poor Prognosis and T-Cell Dysfunction in Non-small Cell Lung Cancer.Tuberculosis and respiratory diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) have high aggression and immunosuppression characteristics, with treatment limitation and poor clinical prognosis. Glioma-associated macrophages and microglia (GAMs) constitute the majority immune cells in the tumor microenvironment (TME). Differential molecular characteristics in GBM are related to the poor prognosis and result in therapeutic resistance. Previous research revealed that elevated SERPINA3 expression portends a dismal prognosis for glioma patients. However, the relationship between SERPINA3 and glioma malignant progression, as well as its association with GAMs infiltration, remains unclear. In this study, we explored SERPINA3 levels in different grade glioma tissues and its correlation with GAMs markers. We found that an upregulated of SERPINA3 protein expression in GBM tissues compared to low-grade gliomas. Notably, the expressions of CD68 and IBA1, markers for GAMs, were significantly increased in GBM. Furthermore, we observed a strong correlation between high levels of SERPINA3, CD68, and IBA1 with reduced survival in patients with primary gliomas. Intriguingly, within GBM tissues, we further confirmed the expression of SERPINA3 in GAMs, and that SERPINA3 expression is positively associated with CD68 and IBA1 in primary gliomas, indicating remodeling of the tumor immune microenvironment. This study provides an insight into the therapeutic strategy targeting SERPINA3 in glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.